Delcath Systems’ (NSDQ:DCTH) agreement with the European Institute of Oncology will launch European commercialization for the New York-based company’s Chemostat organ-targeting chemotherapy system.
Under the terms of the deal, Delcath will provide the Milan, Italy-based cancer center with logistics and clinical training support for the Chemostat system, which is awaiting full CE Mark approval.
The Chemostat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ from the rest of the body’s bloodstream. It won CE Mark approval for the a liver cancer indication in April.
Sign up to get our free newsletters delivered straight to your inbox
"After years of clinical research and development, Chemostat will soon be available to patients," Eamonn Hobbs, Delcath president & CEO said in prepared remarks. "We’re pleased that our first launch and training agreement is with such a prestigious institution as the IEO, one of Europe’s premier cancer treatment and research facilities."
Systagenix inks German distribution deal
Systagenix Wound Management teamed up with TRIGOcare GmbH, previously a generic medical devices dealer, to distribute Systagenix products in Germany.
“Together Systagenix and TRIGOcare offer a complete assortment of wound care products to meet the needs of any care model in every price segment,” according to a press release.
McKesson GPO inks deal with Bio-Reference Labs
Bio-Reference Laboratories Inc. (NSDQ: BRLI) landed a purchasing agreement with McKesson Specialty Health group purchasing organization, the Onmark GPO.
The agreement gives Onmark’s nationwide system of community-based practices access to Bio-Reference’s clinical diagnostic services.
Hospital GPOs have been signing a flurry of deals recently, perhaps in response to Medtronic’s (NYSE:MDT) headline-making, Wall-Street-pleasing decision to cut several contracts worth an estimated $2 billion annually.
GPO giant Premier Healthcare Alliance signed contracts earlier this year with med-tech giants Covidien (NYSE:COV), Medline Industries, and Siemens AG (NYSE:SI).
